by | Dec 1, 2021 | Publications
Cutis. 2021 Sep;108(3):E25-E28. doi: 10.12788/cutis.0370. ABSTRACT Amyloidosis is not a singular disease but describes a group of diseases that result from abnormalities in protein folding and metabolism, leading to β-sheet polymers and amyloid fibrils. Cutaneous...
by | Nov 30, 2021 | Publications
Drugs Today (Barc). 2021 Nov;57(11):665-675. doi: 10.1358/dot.2021.57.11.3343690. ABSTRACT Isatuximab is an IgG1 monoclonal antibody targeting CD38 that has received regulatory approval in combination regimens for patients with relapsed/refractory multiple myeloma....
by | Nov 30, 2021 | Publications
Drugs Today (Barc). 2021 Nov;57(11):653-663. doi: 10.1358/dot.2021.57.11.3319146. ABSTRACT Multiple myeloma is the second most common hematologic malignancy worldwide. Despite the growing number of available therapeutic options and advances in the treatment since the...
by | Nov 23, 2021 | Publications
Zhonghua Zhong Liu Za Zhi. 2021 Nov 23;43(11):1209-1214. doi: 10.3760/cma.j.cn112152-20200109-00016. ABSTRACT Objective: To compare the clinical features, clinical efficacy, and prognosis of patients with double-hit and non-double-hit high-risk multiple myeloma (MM)...
by | Nov 23, 2021 | Publications
BMJ Case Rep. 2021 Nov 18;14(11):e243663. doi: 10.1136/bcr-2021-243663. ABSTRACT Multiple myeloma (MM) patients live longer due to more effective treatment, and we now see previously uncommon manifestations of MM, like extramedullary disease. We present a case of a...
by | Nov 20, 2021 | Publications
Zhonghua Xue Ye Xue Za Zhi. 2021 Oct 14;42(10):840-845. doi: 10.3760/cma.j.issn.0253-2727.2021.10.008. ABSTRACT Objective: To investigate the interference of daratumumab on immunofixation electrophoresis after treating plasma cell diseases and methods to eliminate the...
